Biovica International AB (OSTO:BIOVIC B)

kr 2.6 0.2 (8.33%) Market Cap: 218.54 Mil Enterprise Value: 121.52 Mil PE Ratio: 0 PB Ratio: 1.61 GF Score: 37/100

Q2 2023 Biovica International AB Earnings Call Transcript
Dec 15, 2022

kr8.29 (-2.01%)

Earnings
Biovica International AB Market update FDA clearance Transcript
Aug 18, 2022
Q4 2022 Biovica International AB Earnings Call Transcript
Jun 16, 2022

kr34.38 (-3.74%)

Earnings
Biovica International AB Corporate Analyst Meeting Transcript
May 17, 2022
Q3 2022 Biovica International AB Earnings Call Transcript
Mar 15, 2022

kr27.85 (+4.84%)

Earnings
Q2 2022 Biovica International AB Earnings Call Transcript
Dec 01, 2021

kr38 (-5.19%)

Earnings
Q1 2022 Biovica International AB Earnings Call Transcript
Sep 02, 2021

kr58.28 (-0.17%)

Earnings
Biovica International AB CEO's Presentation Annual General Meeting 2021 - Pre-Recorded Transcript
Aug 27, 2021
Q4 2021 Biovica International AB Earnings Call Transcript
Jun 18, 2021

kr45.71 (-3.14%)

Earnings
Biovica International AB Capital Markets Day (Virtual) Transcript
Jun 09, 2021
Q3 2021 Biovica International AB Earnings Call Transcript
Mar 18, 2021

kr41.36 (+6.36%)

Earnings
Q2 2021 Biovica International AB Earnings Call Transcript
Dec 08, 2020

kr45.42 (+0.22%)

Earnings

Q4 2022 Biovica International AB Earnings Call Transcript

Jun 16, 2022 / 01:00PM GMT

Release Date Price: kr34.38 (-3.74%)

Transcript

Operator

Hello, and welcome to the Biovica International audiocast with teleconference Q4 [2022]. (Operator Instructions).

Today, I'm pleased to present CEO, Anders Rylander. Please begin your meeting.

Anders Rylander;publ;CEO;Director

Biovica International AB

()-&

Thank you very much, and welcome, everyone, to this fourth quarter interim report earnings call for Biovica.

So if we move right away to Slide #2, we have the presenters for today. So first of all, it's me, Anders Rylander, the CEO of the company. We have Cecilia Driving, our CFO; and then Amy Williams, Head of Clinical Development and Medical Affairs that will also present.

And the agenda for today, if you move to next slide, Slide #3, is that I will be performing an introduction, short -- very short about the company and the product.

We'll go through the highlights of the fourth quarter, and then Amy will take us through the clinical results that we presented during this period. And Cecilia will take us through the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.